Evolus (EOLS) Misses Q1 EPS by 21c, Misses on Revenue; Offers FY25 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Evolus Reports First Quarter 2025 Results
May 7, 2025 4:05 PM EDTGlobal Net Revenue of $68.5 Million for Q1 2025, Up 15.5% from Q1 2024 Meaningfully Outperformed Toxin Market Share Guidance Assumptions in Slower Market GAAP Operating Loss of $15.2 Million and Non-GAAP Operating Loss of $5.5 Million for the First Quarter; Remains On Track to Achieving Positive Non-GAAP Operating Income on a Consolidated Basis for the Full-Year 2025 Evolysse Launched in Q2 and Off to a Strong Start Reaffirms 2025 Net Revenue Guidance of $345 Million to $355 Million; Evolysse and Estyme® Injectable Hyaluronic Acid (HA) Gels Anticipated to Contribute 8 to 10% of Total Revenue for the Full-Year... More
